Paricalcitol Versus Calcitriol for the Management of Renocardiac Syndrome in Renal Transplant Patients
Status:
Completed
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
We hypothesize that paricalcitol and calcitriol in dose-dependent manner are effective for
the management of chronic allograft dysfunction (CAD), protection and repair of kidney and
heart, management of chronic renocardiac syndrome (CRS). We assume that paricalcitol can have
some advantages if compare with calcitriol or cholecalciferol due to absence of calcemic and
phosphatemic complications alongside with great beneficial potential.
Phase:
Phase 4
Details
Lead Sponsor:
Ural Medical University Ural State Medical University
Collaborators:
De Haar Research Foundation Ural Institute of Cardiology
Treatments:
Calcitriol Cholecalciferol Ergocalciferols Vitamin D Vitamins